Inhibikase Therapeutics Inc. (IKT)
NASDAQ · Healthcare
Inhibikase Therapeutics Inc. Income Statement 2020–2024
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|
| Revenues | |||||
| Revenue | 0 | 260,501 | 123,440 | 3.1M | 698,468 |
| Gross Profit | — | — | — | — | — |
| Profitability | |||||
| Operating Income | -28.6M | -20.1M | -18.1M | -14.8M | -2.8M |
| EBITDA | — | — | — | — | — |
| Net Income | -27.5M | -19.0M | -18.1M | -14.8M | -2.8M |
| Per Share Data | |||||
| EPS (diluted) | $-1.16 | $-3.16 | $-4.28 | $-0.81 | — |
| Shares Outstanding (dil.) | 24M | 6M | 4M | 18M | 10M |
Inhibikase Therapeutics Inc. Income Statement — FAQ
Inhibikase Therapeutics Inc. (IKT) income statement over the last 5 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see IKT's income statement history?
The chart and table above show Inhibikase Therapeutics Inc.'s income statement by year and by quarter, including the growth rate.